PD-L1 expression ensures candidacy for PD-L1 inhibitors across a wide range of tumor types, such as advanced/metastatic NSCLC, head and neck squamous cell carcinoma, advanced/metastatic urothelial carcinoma, and gastric or gastroesophageal junction adenocarcinoma (23). Here, CD274 is linked to neoplasm.